Genenta Science of Milan Raises $14.6 Million in Funding Led by China Investor
publication date: Sep 12, 2019
Genenta Science, a Milan biotech, raised $14.6 million in its third funding, led by Shanghai's Qianzhan Investment Management (QZ) and Fidim, an Italian family fund. Genenta is developing gene therapies for cancer using autologous hematopoietic stem progenitor cells (HSPCs) that contain an engineered gene for a tumor-related cytokine. It aims to trigger interferon-α expression, preventing relapses by rebuilding the patient’s immune system within the tumor. The company's lead product is Temferon, which has started trials in patients with early relapse multiple myeloma and newly diagnosed glioblastoma multiforme. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.